<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2413-4341</journal-id>
<journal-title><![CDATA[Revista Paraguaya de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. parag. reumatol.]]></abbrev-journal-title>
<issn>2413-4341</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Paraguaya de Reumatología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2413-43412021000100002</article-id>
<article-id pub-id-type="doi">10.18004/rpr/2021.07.01.2</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Perfil epidemiológico y clínico de pacientes con Síndrome de Sjögren del Departamento de Reumatología del Hospital de Clínicas- Proyecto Psecopy. Datos preliminares]]></article-title>
<article-title xml:lang="en"><![CDATA[Epidemiological and clinical profile of patients with Sjögren&#8216;s Syndrome of the Rheumatology Department of the Hospital de Clínicas. Psecopy Project. Preliminary data]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vázquez]]></surname>
<given-names><![CDATA[Marcos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pineda]]></surname>
<given-names><![CDATA[Alexis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valinotti]]></surname>
<given-names><![CDATA[Vannia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Paats]]></surname>
<given-names><![CDATA[Astrid]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[Rodrigo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[Elías]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Asunción Facultad de Ciencias Médicas Hospital de Clínicas, Departamento de Reumatología]]></institution>
<addr-line><![CDATA[Asunción ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2021</year>
</pub-date>
<volume>7</volume>
<numero>1</numero>
<fpage>2</fpage>
<lpage>6</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2413-43412021000100002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2413-43412021000100002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2413-43412021000100002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN: El síndrome de Sjögren es una enfermedad autoinmune sistémica caracterizada por la sequedad de mucosas y compromiso sistémico. El objetivo del presente estudio fue describir las características clínico epidemiológicas de los pacientes con Síndrome de Sjögren primario incluidos en la cohorte Psecopy que reúnan los criterios ACR/EULAR 2016 y que hayan acudido al Departamento de Reumatología del Hospital de Clínicas de San Lorenzo. Resultados: Se incluyeron 33 pacientes con Síndrome de Sjögren primario. De los cuales 31 (93,93%) pertenecían al género femenino y 2 (6,01%) al género masculino. Con una edad promedio al momento del diagnóstico de Sjögren primario de 46,12 ańos. Y un tiempo de duración de la enfermedad con una media de 2,10 ańos. Las comorbilidades más frecuentemente asociadas fueron la hipertensión arterial (21,21%) seguido del hipotiroidismo (18,18%). A estos pacientes se les realizó la biopsia salival por no cumplir criterios, en el 12,12 % de los pacientes según criterios de Chisholm y Mason, donde se encontró un focus score predominante de 3. En relación al ESSDAI se encontró un compromiso articular en 51,51 %, glandular en el 54,54 %, articular en 51,51%, pulmonar, linfadenopatía y dominio biológico en un 12,12%, hematológico y dominio constitucional en un 9,09%, cutáneo y renal en un 6,06%, sistema nervioso central y periférico en un 3,03%. Se destaca también la baja actividad de la enfermedad en un 63,63%, moderada actividad en un 21,21% y alta actividad en un 15,15% según la escala de ESSDAI. No se encontraron neoplasias.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT: Sjögren&#8216;s syndrome is a systemic autoimmune disease characterized by dry mucous membranes and systemic involvement. The aim of the present study was to describe the clinical epidemiological characteristics of patients with primary Sjögren&#8216;s Syndrome included in the Psecopy cohort who meet the ACR/EULAR 2016 criteria and evaluated at the Rheumatology Department of the Hospital de Clínicas of San Lorenzo. Results: 33 patients with primary Sjögren&#8216;s syndrome were included, of which 31 (93.93%) were females and 2 (6.01%) were males. The average age at the time of diagnosis of primary Sjögren&#8216;s syndrome was 46.12 years. The average duration of the disease was 2.10 years. The most frequently associated comorbidities were arterial hypertension (21.21%) followed by hypothyroidism (18.18%). Salivary biopsy was performed on 12.12% of patients that did not meet Chisholm and Mason criteria, and a predominant focus score of 3 was found. In relation to ESSDAI, articular involvement was found in 51.51%, glandular in 54.54%, articular in 51.51%, pulmonary, lymphadenopathy and biological domain in 12.12%, hematological and constitutional domain in 9.09%, cutaneous and renal in 6.06%, central and peripheral nervous system in 3.03% of patients. Low disease activity was found in 63.63% of patients, while moderate and high activity was found in 21.21% and 15.15% of patients respectively, according to the ESSDAI scale. No neoplasms were found.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Síndrome de Sjögren]]></kwd>
<kwd lng="es"><![CDATA[Características clínicas]]></kwd>
<kwd lng="en"><![CDATA[Sjogren&#8216;s syndrome]]></kwd>
<kwd lng="en"><![CDATA[Clinical features.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kvarnström]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ottosson]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Nordmark]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Wahren-Herlenius]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incident cases of primary Sjögren syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics]]></article-title>
<source><![CDATA[Scandinavian journal of rheumatology]]></source>
<year>2015</year>
<volume>44</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>135-42</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weng]]></surname>
<given-names><![CDATA[M. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Y. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[M. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[T. H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and mortality of treated primary Sjogren: syndrome in Taiwan: a population-based study]]></article-title>
<source><![CDATA[The Journal of rheumatology]]></source>
<year>2011</year>
<volume>38</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>706-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maldini]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Seror]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Fain]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Dhote]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Amoura]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[De Bandt]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of primary Sjögren syndrome in a French multiracial/multiethnic area]]></article-title>
<source><![CDATA[Arthritis care &amp; research]]></source>
<year>2014</year>
<volume>66</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>454-63</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yamamoto-Fukuda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Direct infection of primary salivary gland epithelial cells by human T lymphotropic virus type I in patients with Sjögren syndrome]]></article-title>
<source><![CDATA[Arthritis Rheumatol]]></source>
<year>2015</year>
<volume>67</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1096-106</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reveille]]></surname>
<given-names><![CDATA[J. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[R. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Provost]]></surname>
<given-names><![CDATA[T. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Bias]]></surname>
<given-names><![CDATA[W. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Arnett]]></surname>
<given-names><![CDATA[F. C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary Sjögren syndrome and other autoimmune diseases in families. Prevalence and immunogenetic studies in six kindreds]]></article-title>
<source><![CDATA[Annals of internal medicine]]></source>
<year>1984</year>
<volume>101</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>748-56</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quartuccio]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Isola]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Corazza]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos-Casals]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Retamozo]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Ragab]]></surname>
<given-names><![CDATA[G. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of the classification criteria for cryoglobulinaemic vasculitis]]></article-title>
<source><![CDATA[Rheumatology (Oxford, England)]]></source>
<year>2014</year>
<volume>53</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2209-13</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Retamozo]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Gheitasi]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Quartuccio]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Kostov]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Corazza]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bové]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sisó-Almirall]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients]]></article-title>
<source><![CDATA[Rheumatology (Oxford, England)]]></source>
<year>2016</year>
<volume>55</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1443-51</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramos-Casals]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Solans]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosas]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Camps]]></surname>
<given-names><![CDATA[M. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Del Pino-Montes]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2008</year>
<volume>87</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>210-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramos-Casals]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Tzioufas]]></surname>
<given-names><![CDATA[A. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Font]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary Sjögren syn- drome: new clinical and therapeutic concepts]]></article-title>
<source><![CDATA[Annals of the rheumatic diseases]]></source>
<year>2005</year>
<volume>64</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>347-54</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyriakidis]]></surname>
<given-names><![CDATA[N. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Kapsogeorgou]]></surname>
<given-names><![CDATA[E. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Gourzi]]></surname>
<given-names><![CDATA[V. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Konsta]]></surname>
<given-names><![CDATA[O. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Baltatzis]]></surname>
<given-names><![CDATA[G. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Tzioufas]]></surname>
<given-names><![CDATA[A. G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway]]></article-title>
<source><![CDATA[Clinical and experimental immunology]]></source>
<year>2014</year>
<volume>178</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>548-60</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Casciola-Rosen]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[A. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Kapsogeorgou]]></surname>
<given-names><![CDATA[E. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Cheadle]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Tzioufas]]></surname>
<given-names><![CDATA[A. G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Precise probes of type II inter- feron activity define the origin of interferon signatures in target tissues in rheumatic diseases]]></article-title>
<source><![CDATA[Proceedings of the National Academy of Sciences of the United States of America]]></source>
<year>2012</year>
<volume>109</volume>
<numero>43</numero>
<issue>43</issue>
<page-range>17609-14</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nocturne]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Mariette]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sjögren Syndrome-associated lympho- mas: an update on pathogenesis and management]]></article-title>
<source><![CDATA[British journal of haematology]]></source>
<year>2015</year>
<volume>168</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>317-27</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nocturne]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Boudaoud]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Miceli-Richard]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Viengchareun]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Lazure]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Nititham]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Germline and somatic genetic varia- tions of TNFAIP3 in lymphoma complicating primary Sjogren syndrome]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2013</year>
<volume>122</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>4068-76</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fabini]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Rutjes]]></surname>
<given-names><![CDATA[S. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmermann]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Pruijn]]></surname>
<given-names><![CDATA[G. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Steiner]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of the molecular composition of Ro ribo nucleoprotein complexes. Identification of novel Y RNA-binding proteins.]]></article-title>
<source><![CDATA[European journal of biochemistry]]></source>
<year>2000</year>
<volume>267</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2778-89</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mekinian]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nicaise-Roland]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Chollet-Martin]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Fain]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Crestani]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-SSA Ro52/Ro60 antibody testing by immunodot could help the diagnosis of Sjogren syndrome in the absence of anti-SSA/SSB antibodies by ELISA]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2013</year>
<volume>52</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2223-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seror]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Ravaud]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Bowman]]></surname>
<given-names><![CDATA[S. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Baron]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Tzioufas]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Theander]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR Sjogren syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren syndrome]]></article-title>
<source><![CDATA[Annals of the rheumatic diseases]]></source>
<year>2010</year>
<volume>69</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1103-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skopouli]]></surname>
<given-names><![CDATA[F. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Barbatis]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Moutsopoulos]]></surname>
<given-names><![CDATA[H. M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liver involvement in primary Sjögren syndrome]]></article-title>
<source><![CDATA[British journal of rheumatology]]></source>
<year>1994</year>
<volume>33</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>745-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartoloni]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Baldini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schillaci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Quartuccio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Priori]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carubbi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular disease risk burden in primary Sjögren syndrome: results of a population-based multicentre cohort study]]></article-title>
<source><![CDATA[Journal of internal medicine]]></source>
<year>2015</year>
<volume>278</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>185-92</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazarus]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Isenberg]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of additional autoimmune diseases in a population of patients with primary Sjögren syndrome]]></article-title>
<source><![CDATA[Annals of the rheumatic diseases]]></source>
<year>2005</year>
<volume>64</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1062-4</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fukuda]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Arisue]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shindoh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between sialographic findings of parotid glands and histopathologic finding of labial glands in Sjögren syndrome. Relation to clinical and immunologic findings.]]></article-title>
<source><![CDATA[Oral surgery, oral medicine, and oral pathology]]></source>
<year>1991</year>
<volume>72</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>675-80</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bowman]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pillemer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jonsson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Asmussen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vitali]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Manthorpe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contributors to and participants at the work- shop. Revisiting Sjögren syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK]]></article-title>
<source><![CDATA[Rheumatology (Oxford, England)]]></source>
<year>2001</year>
<volume>40</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1180-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seror]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gottenberg]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Devauchelle-Pensec]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dubost]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Le Guern]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of systemic disease activity is complementary to assessment of patients symptoms in primary Sjogren syndrome]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2011</year>
<volume>70</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>505</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Theander]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vasaitis]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Baecklund]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nordmark]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Warfvinge]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Liedholm]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren syndrome]]></article-title>
<source><![CDATA[Annals of the rheumatic diseases]]></source>
<year>2011</year>
<volume>70</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1363-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
